What is Modifier CS (Cost-Sharing Waived for COVID-19 Testing)? Definition, Formula, and Benchmark

Modifier CS (Cost-Sharing Waived) identifies services for which cost-sharing is waived under federal COVID-19 response legislation including the Families First Coronavirus Response Act (FFCRA) and the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The modifier signals to the payer that patient deductible, copayment, and coinsurance should be waived for the service, and the payer should process the claim as fully covered without patient financial responsibility.

The scope of Modifier CS evolved during the COVID-19 public health emergency (PHE). Initially it applied narrowly to COVID-19 testing (specimen collection, laboratory analysis, related evaluation services when the visit resulted in a test order). Subsequent policy guidance extended Modifier CS application to certain COVID-19 treatment-related services, vaccine administration, and related evaluation and management visits, though specific scope varied by payer and time period.

Use requires that the service meets the eligibility criteria for cost-sharing waiver. For COVID testing, the service must be related to diagnosing or screening for SARS-CoV-2. The E/M visit leading to a COVID test order is typically eligible if the test is medically necessary and documented; visits not leading to a test order generally do not qualify. Vaccine administration services have their own specific billing and modifier guidance.

Payer acceptance and implementation varied during the PHE. Medicare issued guidance specifying how Modifier CS interacts with Medicare processing; commercial payers generally followed federal requirements but with variation in implementation. As the PHE officially ended (May 2023), the scope of federally-mandated cost-sharing waiver changed, and payer acceptance of Modifier CS shifted. Practices should consult current payer guidance rather than assuming Modifier CS continues to apply broadly.

For RCM operations, Modifier CS required careful implementation during the PHE because its application changed patient billing mechanics. Eligible services with Modifier CS result in full payer payment with no patient responsibility; front-desk collection processes needed to accommodate the waived-cost-sharing scenario. Post-PHE, practices should audit historical Modifier CS claims to confirm appropriate application, particularly for any still-open claims or disputes. Recoupment by payers for inappropriate Modifier CS application is a real post-PHE risk; practices should have documentation supporting each Modifier CS claim's eligibility.

Denial and audit patterns associated with Modifier CS include application to ineligible services (non-COVID services incorrectly flagged), application outside the eligibility window, and failure to apply when eligibility existed. Because the regulatory landscape shifted multiple times during the PHE, practices with high Modifier CS usage should conduct retrospective audit to identify application errors and coordinate with compliance to address systemic issues.